LIVE WEBINAR: TARGATT Unique Technology for Antibody Engineering & Screening - 02/10/21 | ASC

REGISTER NOW

FREE Webinar: TARGATTTM Unique Technology for Antibody Engineering & Screening 
Presenter: Ruby Tsai, PHD, CEO
Date: February 10, 2021 
Time: 10am PST 
Duration: 45 min + Q&A 

Applied StemCell's TARGATT™ site-specific transgene knockin technology provides a very efficient platform for stable cell line generation and for mammalian cell-based library screening. For this, TARGATT™ Master Cell Lines are engineered to carry an integrase recognition landing pad, "attP" in a preselected, intergenic, safe harbor locus. The TARGATT™ integrase then mediates unidirectional recombination between the attP sites in the cell line and attB sites on the donor plasmid to integrate the gene of interest into the specific locus. - Controlled copy number insertion: one copy per cell - Low biosafety level: eliminate the need for virus-based libraries - High integration efficiency (10-30%): efficiency will impact attainable library sizes - Consistent expression across constructs (defined locus) - Medium to high protein expression We have TARGATT™ Master Cell Lines available in the HEK293, CHO, and iPSC cell backgrounds.

Webinar Topics: 

  • Overview of TARGATTTM Technology and Comparison
  • Stable Cell Lines for Bioproduction
  • Naïve Mammalian Based Library Construction

About the Speaker:

Dr. Chen-Tsai received her PhD from Cornell University and did her post-doc research at Stanford University. She has been doing research in genome editing and stem cells over 25 years. Prior to joining ASC, Dr. Chen-Tsai worked at Stanford University for 16 years as the Director of Transgenic Research Center and Associate Director of the Stanford Cancer Institute, overseeing nine research technology labs. Her research at Stanford focused on using Parkinson patient-speci­fic iPS cell lines and their differentiation to dopaminergic neurons as a disease model-in-a-dish. She is a co-inventor of the TARGATT™ integrase technology for site-speci­fic gene insertion. Dr. Chen-Tsai is an author of many scienti­fic papers and holder of over ­fifteen patents. Dr. Chen-Tsai is a co-founder and CEO of Applied StemCell.

About Applied StemCell, Inc.

Applied StemCell, Inc. (ASC) is a fast-growing Gene & Cell Therapy CRO headquartered in California, USA. ASC was founded in 2008 with a goal to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry. With more than 12 years of experience in genome editing and stem cell technologies, ASC is proud to develop innovative technology platforms offering services and products in the field of Stem Cells (iPSCs/ESCs, differentiated cells) and animal/cell models for disease modeling, antibody discovery & screening, bioproduction, AAV potency assays, cell therapy and regenerative medicine. Our Cell and Gene Therapy Bioservice platform also includes consultation for Pre-IND filing and CMC processes.

More information can be found at www.appliedstemcell.com.

Media Contact:
Maki Ogawa
Marketing Director, Applied StemCell, Inc.
408-773-8007
maki.ogawa@appliedstemcell.com

Google